» Articles » PMID: 37240173

Natural Products As the Potential to Improve Alzheimer's and Parkinson's Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 May 27
PMID 37240173
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease and Parkinson's disease are the two most common neurodegenerative diseases in the world, and their incidence rates are increasing as our society ages. This creates a significant social and economic burden. Although the exact cause and treatment methods for these diseases are not yet known, research suggests that Alzheimer's disease is caused by amyloid precursor protein, while α-synuclein acts as a causative agent in Parkinson's disease. The accumulation of abnormal proteins such as these can lead to symptoms such as loss of protein homeostasis, mitochondrial dysfunction, and neuroinflammation, which ultimately result in the death of nerve cells and the progression of neurodegenerative diseases. The medications currently available for these diseases only delay their progression and have many adverse effects, which has led to increased interest in developing natural products with fewer adverse effects. In this study, we selected specific keywords and thesis content to investigate natural products that are effective in treating Alzheimer's and Parkinson's diseases. We reviewed 16 papers on natural products and found that they showed promising mechanisms of action such as antioxidant, anti-inflammatory, and mitochondrial function improvement. Other natural products with similar properties could also be considered potential treatments for neurodegenerative diseases, and they can be consumed as part of a healthy diet rather than as medicine.

Citing Articles

Nutritional and dietary clinical trials for Parkinson's disease: a narrative review.

Giannakis A, Chondrogiorgi M, Konitsiotis S, Sidiropoulos C J Neural Transm (Vienna). 2025; 132(4):519-536.

PMID: 40047855 DOI: 10.1007/s00702-025-02901-7.


Network pharmacology combined with experimental validation show that apigenin as the active ingredient of Campsis grandiflora flower against Parkinson's disease by inhibiting the PI3K/AKT/NF-κB pathway.

Liu K, An J, Zhang J, Zhao J, Sun P, He Z PLoS One. 2024; 19(10):e0311824.

PMID: 39383141 PMC: 11463827. DOI: 10.1371/journal.pone.0311824.


Myricetin mitigates motor disturbance and decreases neuronal ferroptosis in a rat model of Parkinson's disease.

Gu S, Xie Z, Gu M, Wang C, Xu L, Gao C Sci Rep. 2024; 14(1):15107.

PMID: 38956066 PMC: 11219851. DOI: 10.1038/s41598-024-62910-6.


The Potentiality of Natural Products and Herbal Medicine as Novel Medications for Parkinson's Disease: A Promising Therapeutic Approach.

So Y, Lee J, Yang G, Yang G, Kim S, Lee J Int J Mol Sci. 2024; 25(2).

PMID: 38256144 PMC: 10816678. DOI: 10.3390/ijms25021071.


Neuroprotective Iridoids and Lignans from .

Ye M, Lin X, Wang Q, Yang B, Wang C Molecules. 2023; 28(15).

PMID: 37570763 PMC: 10421132. DOI: 10.3390/molecules28155793.

References
1.
Bonifacio M, Palma P, Almeida L, Soares-da-Silva P . Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev. 2007; 13(3):352-79. PMC: 6494163. DOI: 10.1111/j.1527-3458.2007.00020.x. View

2.
Brooks D . Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000; 68(6):685-9. PMC: 1736955. DOI: 10.1136/jnnp.68.6.685. View

3.
Zhu B, Patel U, Cai M, Conney A . O-Methylation of tea polyphenols catalyzed by human placental cytosolic catechol-O-methyltransferase. Drug Metab Dispos. 2000; 28(9):1024-30. View

4.
Marsh S, Blurton-Jones M . Examining the mechanisms that link β-amyloid and α-synuclein pathologies. Alzheimers Res Ther. 2012; 4(2):11. PMC: 4054672. DOI: 10.1186/alzrt109. View

5.
Chong C, Zhou Z, Razmovski-Naumovski V, Cui G, Zhang L, Sa F . Danshensu protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. Neurosci Lett. 2013; 543:121-5. DOI: 10.1016/j.neulet.2013.02.069. View